Cagrilintide

Summary

Cagrilintide (CHEMBL4802169) is a phase-3 clinical-stage protein targeting CALCR; indicated across 6 conditions including obesity disorder and type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Targets: 1 (CALCR)
• Indications: 6 conditions
• Clinical trials: 38

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802169
Name	Cagrilintide
Type	Protein
Max phase	3

Also known as: Cagrilintide, Cagrilintide component of cagrisema, CAGRILINTIDE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CALCR	CT receptor	Agonist	9.54	0%	P30988
	AMY3 receptor	Agonist	9.46

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Calcitonin receptor, Calcitonin-gene-related peptide receptor, CALCRL/RAMP1, Amylin receptor AMY1, CALCR/RAMP1, Amylin receptor AMY3; CALCR/RAMP3, Adrenomedullin receptor, AM2; CALCRL/RAMP3, Amylin receptor AMY2; CALCR/RAMP2.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
RAMP1	10.73	EC50	0.02	nM	CHEMBL_ACT_25914942
CALCR	10.64	EC50	0.02	nM	CHEMBL_ACT_25914938
RAMP2	10.37	EC50	0.04	nM	CHEMBL_ACT_25914946
RAMP3	10.33	EC50	0.05	nM	CHEMBL_ACT_25914950
RAMP1	6.25	EC50	562.3	nM	CHEMBL_ACT_25914954
RAMP3	6.12	EC50	758.6	nM	CHEMBL_ACT_25914962

Target pathways

Aggregated over 1 target gene(s): CALCR.

Top Reactome pathways

7 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	1	CALCR
Signaling by GPCR	1	CALCR
Class B/2 (Secretin family receptors)	1	CALCR
GPCR downstream signalling	1	CALCR
G alpha (s) signalling events	1	CALCR
Calcitonin-like ligand receptors	1	CALCR
GPCR ligand binding	1	CALCR

Dominant GO biological processes

GO term	Targets
ossification	1
cell surface receptor signaling pathway	1
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1
positive regulation of cytosolic calcium ion concentration	1
positive regulation of gene expression	1
negative regulation of ossification	1
osteoclast differentiation	1
regulation of mRNA stability	1
positive regulation of calcium-mediated signaling	1
response to glucocorticoid	1
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
positive regulation of ERK1 and ERK2 cascade	1
calcitonin family receptor signaling pathway	1
amylin receptor signaling pathway	1
positive regulation of cAMP/PKA signal transduction	1

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obesity disorder	3	MONDO:0011122	EFO:0001073
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
liver disorder	2	MONDO:0005154	EFO:0001421
nutritional disorder	1	MONDO:0005137	EFO:0001069

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 38.

Phase distribution

Phase	Trials
PHASE1	18
PHASE3	16
PHASE2	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05567796	PHASE3	ACTIVE_NOT_RECRUITING	A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05669755	PHASE3	ACTIVE_NOT_RECRUITING	REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
NCT06534411	PHASE3	ACTIVE_NOT_RECRUITING	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
NCT06780449	PHASE3	ACTIVE_NOT_RECRUITING	A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT07220642	PHASE3	ACTIVE_NOT_RECRUITING	Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220759	PHASE3	ACTIVE_NOT_RECRUITING	Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07253285	PHASE3	RECRUITING	A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT05394519	PHASE3	COMPLETED	A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
NCT05813925	PHASE3	COMPLETED	A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
NCT05996848	PHASE3	COMPLETED	A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
NCT06065540	PHASE3	COMPLETED	A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06131437	PHASE3	COMPLETED	A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06221969	PHASE3	COMPLETED	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06323161	PHASE3	COMPLETED	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
NCT06323174	PHASE3	COMPLETED	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
NCT06388187	PHASE3	COMPLETED	A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
NCT03856047	PHASE2	COMPLETED	Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
NCT04982575	PHASE2	COMPLETED	Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
NCT06131372	PHASE2	COMPLETED	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
NCT06409130	PHASE2	COMPLETED	Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
NCT07010432	PHASE1	RECRUITING	The Role of the Amylin Analogue Cagrilintide in Bone Metabolism
NCT07411560	PHASE1	RECRUITING	A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese
NCT07527195	PHASE1	RECRUITING	Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
NCT07557953	PHASE1	RECRUITING	A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
NCT07607587	PHASE1	NOT_YET_RECRUITING	Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
NCT02300844	PHASE1	COMPLETED	Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects
NCT02958085	PHASE1	COMPLETED	Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight
NCT03600480	PHASE1	COMPLETED	A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
NCT03787225	PHASE1	COMPLETED	A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity
NCT04074174	PHASE1	COMPLETED	Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pregnant
NCT04209049	PHASE1	COMPLETED	A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function
NCT04940078	PHASE1	COMPLETED	A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
NCT05564104	PHASE1	COMPLETED	A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body
NCT05804162	PHASE1	COMPLETED	A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
NCT06207877	PHASE1	COMPLETED	A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight
NCT06267092	PHASE1	COMPLETED	A Study of How CagriSema Works on Appetite in People With Excess Body Weight
NCT06289504	PHASE1	COMPLETED	A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
NCT06403761	PHASE1	COMPLETED	Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
PRAMLINTIDE	ChEMBL + PubChem	Phase 4 (approved)	CALCR
CALCITONIN SALMON	ChEMBL	Phase 4 (approved)	CALCR